Question special

Given the increasing discussion in medical literature about the utility of peanut component testing, I wanted to ask the authors for their thoughts on the applicability of this to the LEAP study? Was it ever considered to be incorporated as part of the inclusion criteria to stratify patients for risk of peanut allergy, or for any other outcomes?